Original from: Targeted Oncology

The TOBY Test has received breakthrough device designation from the FDA for the early detection of bladder cancer. This designation underscores the significant potential of this innovative urine-based assay to fundamentally alter the landscape of bladder cancer detection and surveillance, offering a much-needed non-invasive alternative to current diagnostic paradigms.

The TOBY Test represents a sophisticated advancement in cancer diagnostics, leveraging the power of urine-based volatilomics combined with AI algorithms. At its core, the technology analyzes volatile organic compounds present in a single urine sample using gas chromatography-mass spectrometry. Proprietary AI then processes these intricate chemical signatures to generate a real-time cancer risk score, providing clinicians with a novel tool for assessment. This one-step, painless procedure contrasts sharply with the invasive and often uncomfortable methodologies that currently dominate bladder cancer management.

Bladder cancer, while the sixth most common cancer in the US, poses unique challenges in its clinical management, primarily due to its high recurrence rate and the subsequent necessity for frequent, invasive surveillance. Cystoscopy, the current gold standard for diagnosis and monitoring, involves the insertion of a rigid or flexible tube with a camera into the bladder, a procedure that, while effective, can be distressing for patients and contributes significantly to the overall cost burden of the disease. The reliance on such invasive tools for ongoing surveillance translates into substantial healthcare expenditures and patient discomfort, highlighting a critical unmet need for more accessible and less burdensome diagnostic options.

Source: FDA Grants Breakthrough Designation for Novel Bladder Cancer Diagnostic